Shoulder care starts with why the joint is sore

PRP may help some shoulders, but the results are mixed

PRP is the short name for platelet-rich plasma. Staff spin blood from your arm and save the portion that has extra platelets. These small parts of blood help close wounds and begin the body's repair work. This is why PRP has been tested for sore cuff tendons. It doesn't mean an old tendon becomes new.

Some studies of irritated or partly torn cuff tendons found modest relief. Other reviews found no added help large enough for people to notice. PRP added during tendon surgery may change how a repair looks later on a scan. People didn't reliably report feeling better, however. That surgery result doesn't show what PRP used alone will do.

Ask which shoulder problem was studied.

Shoulder replacement alternatives depend on how worn the joint is

Advanced arthritis can make the ball-and-socket joint rough, stiff, and sore. Exercise, medicine, and changes in arm use may still ease daily life. They won't restore a badly worn joint. If sleep and motion remain poor, surgery may be worth discussing.

A torn cuff tendon brings a different decision. Many slow tears feel and work better after guided strength work. New weakness after a fall needs a timely exam instead. Care for severe joint wear isn't the same as care for a torn tendon. Ask what the exam and scan show before deciding about surgery.

In Chandler, clinic staff from QC Kinetix can discuss non-surgical regenerative options after checking the shoulder.

Sources

1. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables.

   Brophy RH, et al. — AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.. The Journal of the American Academy of Orthopaedic Surgeons, 2022. DOI: 10.5435/JAAOS-D-21-01233.

2. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. In the MOON Shoulder prospective cohort of 452 patients with symptomatic, ATRAUMATIC full-thickness rotator cuff tears, physical therapy succeeded in more than 70% of patients at 10 years: only 115 (27.0%) had surgery at any point over the decade. Patient-reported outcomes improved with physical therapy and did NOT decline over 10 years in those who never had surgery. The strongest predictor of early surgery was low patient expectation of physical therapy, not tear anatomy.

   Kuhn JE, et al. — The Predictors of Surgery for Symptomatic, Atraumatic Full-Thickness Rotator Cuff Tears Change Over Time: Ten-Year Outcomes of the MOON Shoulder Prospective Cohort.. J Bone Joint Surg Am, 2024. DOI: 10.2106/JBJS.23.00978.

5. UK FROST randomized 503 adults with primary frozen shoulder to manipulation under anaesthesia, arthroscopic capsular release, or early structured physiotherapy with steroid injection. At 12 months every between-group difference on the Oxford Shoulder Score was smaller than the target difference, so NONE of the three was clinically superior. Capsular release carried the most serious adverse events (8 versus 2 with manipulation), and manipulation under anaesthesia was the most cost-effective.

   Rangan A, et al. — Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial.. Lancet, 2020. DOI: 10.1016/S0140-6736(20)31965-6.

6. The GRASP trial randomized 708 adults with a rotator cuff disorder to progressive exercise (up to 6 sessions), a single best-practice advice session, or either of those preceded by a corticosteroid injection. Over 12 months there was no evidence of a difference in Shoulder Pain and Disability Index between progressive exercise and one advice session (adjusted mean difference -0.66, 99% CI -4.52 to 3.20), and no evidence of a difference between having a corticosteroid injection and not having one.

   Hopewell S, et al. — Progressive exercise compared with best practice advice, with or without corticosteroid injection, for the treatment of patients with rotator cuff disorders (GRASP): a multicentre, pragmatic, 2 × 2 factorial, randomised controlled trial.. Lancet, 2021. DOI: 10.1016/S0140-6736(21)00846-1.

7. A 2025 systematic review of 1,125 patients receiving intra-articular injections for glenohumeral osteoarthritis reported a 7.2% overall complication rate and a 3.2% rate of proceeding to surgery. Hyaluronic acid showed consistent though modest benefit, while the evidence for ORTHOBIOLOGICS (PRP, bone marrow aspirate concentrate, mesenchymal stem cells) 'remains limited', mainly because of heterogeneity in design, outcomes and patient characteristics.

   Migliorini F, et al. — Intra-articular injections for shoulder arthritis in adults: a systematic review.. Eur J Med Res, 2025. DOI: 10.1186/s40001-025-03423-4.

8. FDA states verbatim that stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products 'have [not] been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.